Mr. Hugh MacNaught reports

VENTRIPOINT DIAGNOSTICS PUBLISHES WHITEPAPER ON THE USE OF AI IN WHOLE-HEART ANALYSIS

Ventripoint Diagnostics Ltd. has released a white paper comparing the performance of the VMS+ 4.0 advanced automated radiological image processing software/system with the previous basic model, VMS+ 3.0.

This latest advancement of Ventripoint's proprietary technology, VMS+ 4.0, which recently received U.S. Food and Drug Administration 510(k) clearance, delivers a number of significant enhancements, including:

• Artificial-intelligence-assisted automated point placement to improve user workflow efficiency;
• User tools to assist with analysis of the cardiac views;
• Enhanced visualization tools;
• Measurements generated from the 3-D wire mesh:
  • ED volume;
  • ED volume index;
  • ES volume;
  • ES volume index;
  • Ejection fraction;
  • Cardiac output;
  • Cardiac index;
  • Stroke volume;
  • Stroke volume index;
• Reporting of all measurements and derived assumptions.

The VMS+ system connects to standard echocardiography machines, the most widely used cardiac imaging technology globally. The VMS+ 4.0 model uses conventional AI approaches to select anatomical landmarks from standard echocardiogram images, which are then fed into Ventripoint's proprietary knowledge-based reconstruction AI technology to create 3-D visualizations of the heart and calculates volumes and ejection fraction for all four cardiac chambers with accuracy equivalent to MRI. The combination of both AI engines allows for assisting automated point placement of the analysis with improved reliability and confidence in the measurements.

"Ventripoint has deep experience in the application of AI to echocardiography, and we have continued to invest in research and development focused towards enhancing ease of use and integration into clinical workflow," said Ventripoint president and chief executive officer Hugh MacNaught. "During the development process for VMS+ 4.0, our team worked with clinical collaborators to assess the performance of automated features, which is described in the white paper. It is essential that clinicians have confidence and trust in the results. The white paper illustrates the robustness and performance of VMS+. We are excited with the opportunity to offer hospitals an efficient and effective, non-invasive heart-imaging tool. AI enhanced echocardiograms are a fast, affordable and accessible tool for diagnosis and monitoring of the growing numbers of cardiac patients throughout the world."

VMS+ 4.0 has received regulatory clearance in key markets such as the United States, European Union, United Kingdom and Canada, making this latest version of VMS+ available to the global community.

The white paper can be viewed on the Ventripoint website.

About Ventripoint Diagnostics Ltd.

Ventripoint is an industry leader in the application of artificial intelligence to echocardiography. Ventripoint's VMS+ products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to the MRI. This affordable, gold standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

We seek Safe Harbor.